Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial

Onyema Ogbuagu, Hui Wang, Nicolas Margot et al.|The Lancet HIV|2023

Cited by 71